2018 was a big year with respect to big data and analytics. Not just for clinical trials, but the field overall as it relates to the collection of data, the analysis and deep-mining for patterns and the interpretation thereof to inform strategy. Banking and manufacturing are two industries that are particularly adept in the field but health sciences is not far behind.
The importance of compliance was always there, now it’s more important than ever with the proposed fines, how many responses will be submitted to the Draft Guidance and what will the final directive look like?
In this post we look at how clinicaltrials.gov has evolved since its launch in 2000 and how the requirements have expanded to require the registration of additional types of studies and more information about these studies.
CRISPR is a powerful gene-editing technology that's garnered a lot of attention recently. In this post we look at what CRISPR is, why it has created such a buzz, and what it might achieve as it heads toward the clinic.
Containing over 28 million citations, PubMed offers a treasure trove of data from across the life-sciences. But honing down on what you’re looking for can be challenging. We explore what it has to offer on clinical trials – and how easy is it to find.
Timely access to clinical trial data is important for patients and physicians. In this blog post we examine how well sponsors are doing at releasing their clinical trial data, and look at some of the incentives that are in place to encourage the reporting of trial outcomes.
Understanding what your competitors are working on and how it effects your business is key across most industries. The clinical trial arena is no different. Knowing what trials are starting or in progress along with the details of the protocols from past trials can give your company a leg up. Learn more about the importance of clinical trial information as part of your competitive intelligence plan in our new blog post!
With this seemingly unrelenting bad news, what does the future hold for drug development for Alzheimer's Disease (AD)? This post provides a brief overview of the landscape of trials for AD and why there is optimism that DMDs for this devastating condition will be a case of when they will be developed not if.
The Rutuximab patent period is over, and now clinical trial experimentation of the product is available to all industry players, which is creating a huge activity of new trials with the drug. We analyze the data.
In this post we take analyze clinical trials that are operating in 5 or more countries, and we discuss in detail one in particular that has operations in 42 countries.